Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 16/20 | 1.00 |
| ▸ | KCNQ2 | O43526 | 16/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 13/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 13/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | BACE1 | P56817 | 1/20 | 0.68 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134896 | 0.88 | KCNQ3 (0.78) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL14340100 | 0.87 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5215833 | 0.87 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5215207 | 0.85 | KCNQ3 (0.81) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL14516641 | 0.84 | KCNQ3 (0.76) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL509115 | 0.83 | KCNQ3 (0.71) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL509362 | 0.83 | KCNQ3 (0.71) | KCNQ3KCNQ2KCNE1KCNQ1MEN1 | |
| SCHEMBL5217440 | 0.83 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1RAB9A | |
| SCHEMBL367538 | 0.82 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5214418 | 0.81 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1208085-B1 | BENZANILIDES AS POTASSIUM CHANNEL OPENERS | ICAGEN INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-6989398-B2 | Benzanilides as potassium channel openers | ICAGEN, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040157829-A1 | Benzanilides as potassium channel openers | ICAGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6737422-B2 | VOLTAGE-DEPENDENT | ICAGEN, INC. | 2004-05-18 | — | — | US | disclosed |
| US-6605725-B2 | Treating a central or peripheral nervous system disorder or condition through modulation of a voltage-dependent potassium channel | ICAGEN, INC. | 2003-08-12 | — | — | US | disclosed |
| US-6495550-B2 | SUBSTITUTED BENZAMIDO-PYRIDINE DERIVATIVES FOR TREATMENT OF DISORDERS MEDIATED BY POTASSIUM CHANNELS | ICAGEN, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020091122-A1 | Benzanilides as potassium channel openers | ICAGEN, INC. (US) | 2002-07-11 | — | — | US | disclosed |
| US-20020052393-A1 | Benzanilides as potassium channel openers | ICAGEN, INC. (US) | 2002-05-02 | — | — | US | disclosed |
| US-6372767-B1 | NERVOUS SYSTEM DISORDERS WITH HETEROCYCLIC SUBSTITUTED BEMZANILIDES | ICAGEN, INC. | 2002-04-16 | — | — | US | disclosed |
| US-20010049444-A1 | Pyridine-substituted benzanilides as potassium ion channel openers | ICAGEN, INC. | 2001-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157829-A1 | Benzanilides as potassium channel openers | KCNJ2, KCNA3, KCNH2 | KCNQ3 13/4885KCNQ2 6/4885KCNE1 31/4885 |
| US-20020091122-A1 | Benzanilides as potassium channel openers | KCNJ2, KCNA3, KCNH2 | KCNQ3 13/4885KCNQ2 6/4885KCNE1 31/4885 |
| US-20020052393-A1 | Benzanilides as potassium channel openers | KCNJ2, KCNA3, KCNH2 | KCNQ3 13/4885KCNQ2 6/4885KCNE1 31/4885 |
| US-20010049444-A1 | Pyridine-substituted benzanilides as potassium ion channel openers | KCNJ2, KCNJ1, KCNN3 | KCNQ3 18/4885KCNQ2 12/4885KCNE1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.